Unknown analyst
(sound gap) Practical application, who will conduct a presentation. Megan?
Megan Sniecinski
Chief Operating Officer
Thank you. Thank you. Good evening I’m Megan Sniecinski, COO of Praxis. Building on a fantastic 2025, we have continued to execute across our portfolio on our journey to becoming a business, gaining momentum across all four of our late-stage assets.
These are our forward-looking statements. Everything we do at Praxis comes down to one thing, which is to accelerate the delivery of life-changing treatments to patients with central nervous system disorders, many of whom have been waiting for decades. Given our near-term horizon, what lies ahead this year positions us well to accomplish this mission.
I want to use our time today to share a little more about what’s happening in each of our programs, what we’re excited about and what lies ahead for the company. Our broad pipeline has several near-term catalysts and we are moving towards execution to achieve them. Our ulixa NDA for essential essential tremor is under review with a PDUFA date of late January 2027. Prior to that, we have our NDA for rilotrigine under priority review with a PDUFA date of late September.
On our earnings call last week, we also announced that recruitment has been completed for our EMERALD study in broader DEEs with top results read in the fourth quarter of this year. Looking at formatrigine, we have a Phase III study readout for POWER1 this quarter, and we will initiate the POWER3 monotherapy study, which is a milestone that this community has been waiting for, using all the exciting features that formatrigine has to offer.
